Abiopharma

🔍 BROWN MICHAEL S (Director)

Company: REGENERON PHARMACEUTICALS, INC. (REGN)

Report Date: 2026-01-02

Detailed Transactions and Holdings:

• Acquired 155 shares of Common Stock (Direct)
  Date: 2026-01-02 | Code: A | equity_swap_involved: 0 | shares_owned_after: 1,703.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-01-02 | Code: H | nature_of_ownership: by SLAT | shares_owned_after: 5,000.00 | Footnotes: F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-01-02 | Code: H | nature_of_ownership: by Trust | shares_owned_after: 6,162.00
• Acquired 1,962 shares of Non-Qualified Stock Option (right to buy) at $772.76 per share (Derivative)
  Date: 2026-01-02 | Code: A | Expires: 2036-01-02 | equity_swap_involved: 0 | shares_owned_after: 1,962.00 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.
• F2: These shares are held in a trust for the benefit of the reporting person's immediate family members. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
• F3: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.